PET and SPECT in heart failure

Current Cardiology Reports

Volumn 15, Issue 3, 2013, Pages

  Rischpler, Christoph ^a,b   Nekolla, Stephan ^a,b   Schwaiger, Markus ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Heart failure; Molecular imaging; PET; SPECT

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; ADRENALIN C 11; AMMONIA; CARBON 11; FLUORO GALACTO ARGINYLGLYCYLASPARTIC ACID F 18; FLUORODEOXYGLUCOSE F 18; HYDROXYEPHEDRINE C 11; MATRIX METALLOPROTEINASE; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITROGEN 13; PHENYLEPHRINE C 11; RUBIDIUM 82; TETROFOSMIN TC 99M; THALLIUM 201; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CELL THERAPY; CELL TRACKING; DRUG HALF LIFE; DRUG UPTAKE; EARLY DIAGNOSIS; ENZYME ACTIVITY; HEART FAILURE; HEART INNERVATION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE METABOLISM; HUMAN; ISOTOPE LABELING; MYOCARDIAL PERFUSION IMAGING; MYOCARDIAL VIABILITY; NON INVASIVE PROCEDURE; NUCLEAR MEDICINE; POSITRON EMISSION TOMOGRAPHY; RISK ASSESSMENT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 84872283353     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0337-z     Document Type: Article

References (120)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-209.
2. McMurray JJ, Petrie MC, Murdoch DR, Davie AP. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998;19(Suppl P):9-16.
3. Lloyd-Jones DM, Larson MG, Leip EP, et al. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation. 2002;106(24):3068-72. (Pubitemid 35440290)
4. McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am Coll Cardiol. 2002;39 (1):60-9. (Pubitemid 34059862)
5. Levy D, Kenchaiah S, Larson MG, et al. Long-Term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397-402. (Pubitemid 35239711)
6. Roger VL, Weston SA, Redfield MM, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344-50. (Pubitemid 38944258)
7. Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993;22 (4 Suppl A):6A-13. (Pubitemid 23285789)
8. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275(20):1557-62. (Pubitemid 26154241)
9. Kannel WB, Ho K, Thom T. Changing epidemiological features of cardiac failure. Br Heart J. 1994;72(2 Suppl):S3-9. (Pubitemid 24249719)
10. Gheorghiade M, Bonow RO. Chronic heart failure in the United States: a manifestation of coronary artery disease. Circulation. 1998;97(3):282-9. (Pubitemid 28067315)
11. McMurray JJ, Pfeffer MA. Heart failure. Lancet. 2005;365 (9474):1877-89. (Pubitemid 40744967)
12. Hendel RC, Berman DS, Di Carli MF, et al. ACCF/ASNC/ACR/AHA/ASE/SCCT/ SCMR/SNM 2009 Appropriate Use Criteria for Cardiac Radionuclide Imaging: A Report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, the American Society of Nuclear Cardiology, the American College of Radiology, the American Heart Association, the American Society of Echocardiography, the Society of Cardiovascular Computed Tomography, the Society for Cardiovascular Magnetic Resonance, and the Society of Nuclear Medicine. J Am Coll Cardiol. 2009;53(23):2201-29.
13. Davis K, Kennedy JW, Kemp Jr HG, Judkins MP, Gosselin AJ, Killip T. Complications of coronary arteriography from the Collaborative Study of Coronary Artery Surgery (CASS). Circulation. 1979;59(6):1105-12. (Pubitemid 9178546)
14. Bulkley BH, Hutchins GM, Bailey I, Strauss HW, Pitt B. Thallium 201 imaging and gated cardiac blood pool scans in patients with ischemic and idiopathic congestive cardiomyopathy. A clinical and pathologic study. Circulation. 1977;55(5):753-60. (Pubitemid 8090091)
15. Eisenberg JD, Sobel BE, Geltman EM. Differentiation of ischemic from nonischemic cardiomyopathy with positron emission tomography. Am J Cardiol. 1987;59(15):1410-4. (Pubitemid 17093831)
16. Boucher CA, Fallon JT, Johnson RA, Yurchak PM. Cardiomyopathic syndrome caused by coronary artery disease. III: prospective clinicopathological study of its prevalence among patients with clinically unexplained chronic heart failure. Br Heart J. 1979;41(5):613-20. (Pubitemid 9231140)
17. Danias PG,Ahlberg AW, Clark 3rd BA, et al. Combined assessment of myocardial perfusion and left ventricular function with exercise technetium-99m sestamibi gated single-photon emission computed tomography can differentiate between ischemic and nonischemic dilated cardiomyopathy. Am J Cardiol. 1998;82(10):1253-8. (Pubitemid 28541284)
18. Yao SS, Qureshi E, Nichols K, Diamond GA, Depuey EG, Rozanski A. Prospective validation of a quantitative method for differentiating ischemic versus nonischemic cardiomyopathy by technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. Clin Cardiol. 2004;27 (11):615-20. (Pubitemid 39441743)
19. Wu YW, Yen RF, Chieng PU, Huang PJ. Tl-201 myocardial SPECT in differentiation of ischemic from nonischemic dilated cardiomyopathy in patients with left ventricular dysfunction. J Nucl Cardiol. 2003;10(4):369-74.
20. Her SH, Yoon HJ, Lee JM, et al. Adenosine Tc-99m tetrofosmin SPECT in differentiation of ischemic from nonischemic cardiomyopathy in patients with LV systolic dysfunction. Clin Nucl Med. 2008;33(7):459-63.
21. Mody FV, Brunken RC, Stevenson LW, Nienaber CA, Phelps ME, Schelbert HR. Differentiating cardiomyopathy of coronary artery disease from nonischemic dilated cardiomyopathy utilizing positron emission tomography. J Am Coll Cardiol. 1991;17 (2):373-83.
22. Marcassa C, Bax JJ, Bengel F, et al. Clinical value, costeffectiveness, and safety of myocardial perfusion scintigraphy: a position statement. Eur Heart J. 2008;29(4):557-63. (Pubitemid 351264184)
23. Underwood SR, Anagnostopoulos C, Cerqueira M, et al. Myocardial perfusion scintigraphy: the evidence. Eur J Nucl Med Mol Imaging. 2004;31(2):261-91.
24. Gaemperli O, Bengel FM, Kaufmann PA. Cardiac hybrid imaging. Eur Hear J. 2011;32(17):2100-8.
25. Kapur A, Latus KA, Davies G, et al. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study. Eur J Nucl Med Mol Imaging. 2002;29 (12):1608-16.
26. Schinkel AF, Poldermans D, Elhendy A, Bax JJ. Assessment of myocardial viability in patients with heart failure. J Nucl Med. 2007;48(7):1135-46. (Pubitemid 47052654)
27. Perrone-Filardi P, Pace L, Prastaro M, et al. Assessment of myocardial viability in patients with chronic coronary artery disease. Rest-4-hour-24-hour 201Tl tomography versus dobutamine echocardiography. Circulation. 1996;94(11):2712-9. (Pubitemid 26411733)
28. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation. 2004;110(9):1168-76. (Pubitemid 39328205)
29. Schneider CA, Voth E, Gawlich S, et al. Significance of rest technetium-99m sestamibi imaging for the prediction of improvement of left ventricular dysfunction after Q wave myocardial infarction: importance of infarct location adjusted thresholds. J Am Coll Cardiol. 1998;32(3):648-54. (Pubitemid 28435248)
30. Sciagra R, Pellegri M, Pupi A, et al. Prognostic implications of Tc-99m sestamibi viability imaging and subsequent therapeutic strategy in patients with chronic coronary artery disease and left ventricular dysfunction. J Am Coll Cardiol. 2000;36(3):739-45.
31. Bateman TM, Heller GV, McGhie AI, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol. 2006;13(1):24-33. (Pubitemid 43192726)
32. Flotats A, Bravo PE, Fukushima K, Chaudhry MA, Merrill J, Bengel FM. (82)Rb PET myocardial perfusion imaging is superior to (99m)Tc-labelled agent SPECT in patients with known or suspected coronary artery disease. Eur J Nucl Med Mol Imaging. 2012;39(8):1233-9.
33. Murphy ML, Kane JJ, Peng CF, Straub KD. Wall motion and metabolic changes after coronary occlusion and reperfusion. J Surg Res. 1982;32(2):143-9. (Pubitemid 12171445)
34. Higuchi T, Bengel FM. Cardiovascular nuclear imaging: from perfusion to molecular function: non-invasive imaging. Heart. 2008;94(6):809-16. (Pubitemid 351744708)
35. Heller GV, Calnon D, Dorbala S. Recent advances in cardiac PET and PET/CT myocardial perfusion imaging. J Nucl Cardiol. 2009;16(6):962-9.
36. Yoshida K, Mullani N, Gould KL. Coronary flow and flow reserve by PET simplified for clinical applications using rubidium-82 or nitrogen-13-Ammonia. J Nucl Med. 1996;37 (10):1701-12. (Pubitemid 26337184)
37. Bergmann SR, Fox KA, Rand AL, et al. Quantification of regional myocardial blood flow in vivo with H215O. Circulation. 1984;70(4):724-33. (Pubitemid 14020671)
38. Bellina CR, Parodi O, Camici P, et al. Simultaneous in vitro and in vivo validation of nitrogen-13-Ammonia for the assessment of regional myocardial blood flow. J Nucl Med. 1990;31(8):1335-43. (Pubitemid 20245930)
39. Lautamaki R, George RT, Kitagawa K, et al. Rubidium-82 PETCT for quantitative assessment of myocardial blood flow: validation in a canine model of coronary artery stenosis. Eur J Nucl Med Mol Imaging. 2009;36(4):576-86.
40. Rischpler C, Park MJ, Fung GS, Javadi M, Tsui BM, Higuchi T. Advances in PET myocardial perfusion imaging: F-18 labeled tracers. Ann Nucl Med. 2012;26(1):1-6.
41. El Fakhri G, Kardan A, Sitek A, et al. Reproducibility and accuracy of quantitative myocardial blood flow assessment with (82)Rb PET: comparison with (13)N-Ammonia PET. J Nucl Med. 2009;50(7):1062-71.
42. Nitzsche EU, Choi Y, Czernin J, Hoh CK, Huang SC, Schelbert HR. Noninvasive quantification of myocardial blood flow in humans. A direct comparison of the [13N]ammonia and the [15O]water techniques. Circulation. 1996;93(11):2000-6.
43. Tio RA, Dabeshlim A, Siebelink HM, et al. Comparison between the prognostic value of left ventricular function and myocardial perfusion reserve in patients with ischemic heart disease. J Nucl Med. 2009;50(2):214-9.
44. Legrand V, Mancini GB, Bates ER, Hodgson JM, Gross MD, Vogel RA. Comparative study of coronary flow reserve, coronary anatomy and results of radionuclide exercise tests in patients with coronary artery disease. J Am Coll Cardiol. 1986;8(5):1022-32. (Pubitemid 16009085)
45. Weiss MB, Ellis K, Sciacca RR, Johnson LL, Schmidt DH, Cannon PJ. Myocardial blood flow in congestive and hypertrophic cardiomyopathy: relationship to peak wall stress and mean velocity of circumferential fiber shortening. Circulation. 1976;54 (3):484-94.
46. Nitenberg A, Foult JM, Blanchet F, Zouioueche S. Multifactorial determinants of reduced coronary flow reserve after dipyridamole in dilated cardiomyopathy. Am J CardiolAm J Cardiol. 1985;55 (6):748-54. (Pubitemid 15148254)
47. Cecchi F, Olivotto I, Gistri R, Lorenzoni R, Chiriatti G, Camici PG. Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy. N Engl J Med. 2003;349(11):1027-35. (Pubitemid 37087617)
48. Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation. 2002;105(2):186-93. (Pubitemid 34084317)
49. Neglia D, Parodi O, Gallopin M, et al. Myocardial blood flow response to pacing tachycardia and to dipyridamole infusion in patients with dilated cardiomyopathy without overt heart failure. A quantitative assessment by positron emission tomography. Circulation. 1995;92(4):796-804.
50. Drzezga AE, Blasini R, Ziegler SI, Bengel FM, Picker W, Schwaiger M. Coronary microvascular reactivity to sympathetic stimulation in patients with idiopathic dilated cardiomyopathy. J Nucl Med. 2000;41(5):837-44. (Pubitemid 30266028)
51. Camici P, Chiriatti G, Lorenzoni R, et al. Coronary Vasodilation Is Impaired in Both Hypertrophied and Nonhypertrophied Myocardium of Patients with Hypertrophic Cardiomyopathy -A Study with N-13 Ammonia and Positron Emission Tomography. J Am Coll Cardiol. 1991;17(4):879-86.
52. Ghosh N, Rimoldi OE, Beanlands RS, Camici PG. Assessment of myocardial ischaemia and viability: role of positron emission tomography. Eur Heart J. 2010;31(24):2984-95.
53. Inglese E, Leva L, Matheoud R, et al. Spatial and temporal heterogeneity of regional myocardial uptake in patients without heart disease under fasting conditions on repeated whole-body 18F-FDG PET/CT. J Nucl Med. 2007;48(10):1662-9. (Pubitemid 47577344)
54. Fallavollita JA. Spatial heterogeneity in fasting and insulinstimulated (18)F-2-deoxyglucose uptake in pigs with hibernating myocardium. Circulation. 2000;102(8):908-14.
55. Depre C, Vanoverschelde JL, Taegtmeyer H. Glucose for the heart. Circulation. 1999;99(4):578-88. (Pubitemid 29061876)
56. McNulty PH, Jagasia D, Cline GW, et al. Persistent changes in myocardial glucose metabolism in vivo during reperfusion of a limited-duration coronary occlusion. Circulation. 2000;101 (8):917-22. (Pubitemid 30117888)
57. Lopaschuk GD, Stanley WC. Glucose metabolism in the ischemic heart. Circulation. 1997;95(2):313-5. (Pubitemid 27056191)
58. Beanlands RSB, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fuorodeoxyglucose positron emission tomography imaging. Circulation. 1998;98(19):Ii51-6. (Pubitemid 28512165)
59. Di Carli MF, Davidson M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol. 1994;73(8):527-33. (Pubitemid 24142581)
60. D'Egidio G, Nichol G, Williams KA, et al. Increasing Benefit From Revascularization Is Associated With Increasing Amounts of Myocardial Hibernation A Substudy of the PARR-2 Trial. Jacc-Cardiovasc Imag. 2009;2(9):1060-8. Important study demonstrating that patients suffering from ischemic cardiomyopathy with larger amounts of mismatch have a better outcome after revascularization.
61. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography. N Engl J Med. 1986;314(14):884-8. (Pubitemid 16126116)
62. Schinkel AF, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32(7):375-410. (Pubitemid 46881171)
63. Di Carli MF, Maddahi J, Rokhsar S, et al. Long-Term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg. 1998;116 (6):997-1004. (Pubitemid 28553544)
64. Marwick TH, Zuchowski C, Lauer MS, Secknus MA, Williams J, Lytle BW. Functional status and quality of life in patients with heart failure undergoing coronary bypass surgery after assessment of myocardial viability. J Am Coll Cardiol. 1999;33 (3):750-8.
65. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-Analysis. J Am Coll Cardiol. 2002;39(7):1151-8. (Pubitemid 34267418)
66. Dicarli MF, Asgarzadie F, Schelbert HR, et al. Quantitative Relation between Myocardial Viability and Improvement in Heart-Failure Symptoms after Revascularization in Patients with Ischemic Cardiomyopathy. Circulation. 1995;92(12):3436-44.
67. Haas F, Haehnel CJ, Picker W, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease. J Am Coll Cardiol. 1997;30(7):1693-700. (Pubitemid 27521251)
68. Matsunari I, Schricke U, Bengel FM, et al. Extent of cardiac sympathetic neuronal damage is determined by the area of ischemia in patients with acute coronary syndromes. Circulation. 2000;101(22):2579-85. (Pubitemid 30350635)
69. Sasano T, Abraham MR, Chang KC, et al. Abnormal sympathetic innervation of viable myocardium and the substrate of ventricular tachycardia after myocardial infarction. J Am Coll Cardiol. 2008;51(23):2266-75. (Pubitemid 351754990)
70. Bertini M, Schalij MJ, Bax JJ, Delgado V. Emerging role of multimodality imaging to evaluate patients at risk for sudden cardiac death. Circ Cardiovasc Imaging. 2012;5(4):525-35.
71. Bohm M, La Rosee K, Schwinger RH, Erdmann E. Evidence for reduction of norepinephrine uptake sites in the failing human heart. J Am Coll Cardiol. 1995;25(1):146-53.
72. Eisenhofer G, Friberg P, Rundqvist B, et al. Cardiac sympathetic nerve function in congestive heart failure. Circulation. 1996;93 (9):1667-76. (Pubitemid 26131343)
73. The MICAD Research Team. Meta-[radioiodinated]iodobenzylguanidine. Molecular Imaging and Contrast Agent Database (MICAD). Bethesda (MD): ational Center for Biotechnology Information (US). 2004-2012.
74. Dae MW, De Marco T, Botvinick EH, et al. Scintigraphic assessment of MIBG uptake in globally denervated human and canine hearts-implications for clinical studies. J Nucl Med. 1992;33 (8):1444-50.
75. Estorch M, Camprecios M, Flotats A, et al. Sympathetic reinnervation of cardiac allografts evaluated by 123I-MIBG imaging. J Nucl Med. 1999;40(6):911-6. (Pubitemid 29269209)
76. Wieland DM, Brown LE, Rogers WL, et al. Myocardial imaging with a radioiodinated norepinephrine storage analog. J Nucl Med. 1981;22(1):22-31. (Pubitemid 11213140)
77. Carrio I. Cardiac neurotransmission imaging. J Nucl Med. 2001;42(7):1062-76. (Pubitemid 32595307)
78. Flotats A, Carrio I. Cardiac neurotransmission SPECT imaging. J Nucl Cardiol. 2004;11(5):587-602. (Pubitemid 39341804)
79. Simoes MV, Barthel P, Matsunari I, et al. Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J. 2004;25(7):551-7. (Pubitemid 38478547)
80. Jacobson AF, Senior R, Cerqueira MD, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol. 2010;55(20):2212-21. First, large prospective study confirming the usefulness of cardiac sympathetic nerve imaging with 123I-MIBG as an independent prognostic predictor for cardiac events.
81. Agostini D, Verberne HJ, Burchert W, et al. I-123-mIBG myocardial imaging for assessment of risk for a major cardiac event in heart failure patients: insights from a retrospective European multicenter study. Eur J Nucl Med Mol Imaging. 2008;35 (3):535-46.
82. Verberne HJ, Brewster LM, Somsen GA, van Eck-Smit BL. Prognostic value of myocardial 123I-metaiodobenzylguanidine (MIBG) parameters in patients with heart failure: a systematic review. Eur Heart J. 2008;29(9):1147-59. (Pubitemid 351844881)
83. Travin M, Ananthasubramaniam K, Henzlova MJ, Clements IP, Amanullah A, Jacobson AF. Imaging of Myocardial Sympathetic Innervation for Prediction of Cardiac and All-cause Mortality in Heart Failure Patients: analyses From the ADMIRE-HF Trial. Circulation. 2009;120(18):S350-S50.
84. Kioka H, Yamada T, Mine T, et al. Prediction of sudden death in patients with mild-To-moderate chronic heart failure by using cardiac iodine-123 metaiodobenzylguanidine imaging. Heart. 2007;93(10):1213-8. (Pubitemid 47492905)
85. Tamaki S, Yamada T, Okuyama Y, et al. Cardiac iodine-123 metaiodobenzylguanidine imaging predicts sudden cardiac death independently of left ventricular ejection fraction in patients with chronic heart failure and left ventricular systolic dysfunction: results from a comparative study with signal-Averaged electrocardiogram, heart rate variability, and QT dispersion. J Am Coll Cardiol. 2009;53(5):426-35.
86. Buxton AE, Lee KL, Hafley GE, et al. Limitations of ejection fraction for prediction of sudden death risk in patients with coronary artery disease: lessons from the MUSTT study. J Am Coll Cardiol. 2007;50(12):1150-7. (Pubitemid 47375017)
87. Desai AS, Fang JC, Maisel WH, Baughman KL. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-Analysis of randomized controlled trials. JAMA. 2004;292(23):2874-9. (Pubitemid 39628235)
88. Carrio I, Cowie MR, Yamazaki J, Udelson J, Camici PG. Cardiac sympathetic imaging with mIBG in heart failure. JACC Cardiovasc Imaging. 2010;3(1):92-100.
89. Munch G, Nguyen NT, Nekolla S, et al. Evaluation of sympathetic nerve terminals with [(11)C]epinephrine and [(11)C] hydroxyephedrine and positron emission tomography. Circulation. 2000;101(5):516-23. (Pubitemid 30080866)
90. Schwaiger M, Hutchins GD, Kalff V, et al. Evidence for regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography. J Clin Invest. 1991;87 (5):1681-90.
91. Lautamaki R, Tipre D, Bengel FM. Cardiac sympathetic neuronal imaging using PET. Eur J Nucl Med Mol Imaging. 2007;34 Suppl 1:S74-85. (Pubitemid 46957471)
92. Nguyen NT, DeGrado TR, Chakraborty P, Wieland DM, Schwaiger M. Myocardial kinetics of carbon-11-epinephrine in the isolated working rat heart. J Nucl Med. 1997;38(5):780-5.
93. 11C] phenylephrine kinetics to monoamine oxidase activity in normal human heart. J Nucl Med. 1999;40(2):232-8. (Pubitemid 29077083)
94. Raffel DM, Corbett JR, del Rosario RB, et al. Clinical evaluation of carbon-11-phenylephrine: MAO-sensitive marker of cardiac sympathetic neurons. J Nucl Med. 1996;37(12):1923-31. (Pubitemid 26428355)
95. Hartmann F, Ziegler S, Nekolla S, et al. Regional patterns of myocardial sympathetic denervation in dilated cardiomyopathy: an analysis using carbon-11 hydroxyephedrine and positron emission tomography. Heart. 1999;81(3):262-70. (Pubitemid 29116337)
96. 11C]hydroxyephedrine, a specific tracer for sympathetic nerve endings, and its functional correlates in congestive heart failure. Am J Cardiol. 1999;84 (5):568-74. (Pubitemid 29408590)
97. Pietila M, Malminiemi K, Ukkonen H, et al. Reduced myocardial carbon-11 hydroxyephedrine retention is associated with poor prognosis in chronic heart failure. Eur J Nucl Med. 2001;28(3):373-6.
98. Pietila M, Malminiemi K, Vesalainen R, et al. Exercise training in chronic heart failure: beneficial effects on cardiac (11)C-hydroxyephedrine PET, autonomic nervous control, and ventricular repolarization. J Nucl Med. 2002;43(6):773-9. (Pubitemid 34663299)
99. Bengel FM, Permanetter B, Ungerer M, Nekolla SG, Schwaiger M. Relationship between altered sympathetic innervation, oxidative metabolism and contractile function in the cardiomyopathic human heart; a non-invasive study using positron emission tomography. Eur Heart J. 2001;22(17):1594-600. (Pubitemid 32801305)
100. Pfeffer MA, Braunwald E. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation. 1990;81(4):1161-72. (Pubitemid 20119612)
101. Haubner R, Beer AJ, Wang H, Chen X. Positron emission tomography tracers for imaging angiogenesis. Eur J Nucl Med Mol Imaging. 2010;37 Suppl 1:S86-103.
102. Higuchi T, Bengel FM, Seidl S, et al. Assessment of alphavbeta3 integrin expression after myocardial infarction by positron emission tomography. Cardiovasc Res. 2008;78(2):395-403. (Pubitemid 351556104)
103. Meoli DF, Sadeghi MM, Krassilnikova S, et al. Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest. 2004;113(12):1684-91. (Pubitemid 39071660)
104. Makowski MR, Ebersberger U, Nekolla S, Schwaiger M. In vivo molecular imaging of angiogenesis, targeting alphavbeta3 integrin expression, in a patient after acute myocardial infarction. Eur Heart J. 2008;29(18):2201.
105. Sherif HM, Saraste A, Nekolla SG, et al. Molecular imaging of early alphavbeta3 integrin expression predicts long-Term leftventricle remodeling after myocardial infarction in rats. J Nucl Med. 2012;53(2):318-23.
106. Mann DL, Spinale FG. Activation of matrix metalloproteinases in the failing human heart -Breaking the tie that binds. Circulation. 1998;98(17):1699-702. (Pubitemid 28492487)
107. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997;378(3-4):151-60. (Pubitemid 27230597)
108. Cottam D, Rees R. Regulation of matrix metalloproteinases -Their role in tumor invasion and metastasis. Int J Oncol. 1993;2(6):861-72. (Pubitemid 23178382)
109. Ries C, Petrides PE. Cytokine Regulation of Matrix Metalloproteinase Activity and Its Regulatory Dysfunction in Disease. Biol Chem H-S. 1995;376(6):345-55.
110. Su H, Spinale FG, Dobrucki LW, et al. Noninvasive targeted imaging of matrix metalloproteinase activation in a murine model of postinfarction remodeling. Circulation. 2005;112(20):3157-67.
111. Mukherjee R, Brinsa TA, Dowdy KB, et al. Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation. 2003;107(4):618-25. (Pubitemid 36176814)
112. Sahul ZH, Mukherjee R, Song J, et al. Targeted imaging of the spatial and temporal variation of matrix metalloproteinase activity in a porcine model of postinfarct remodeling: relationship to myocardial dysfunction. Circ Cardiovasc Imaging. 2011;4 (4):381-91.
113. Kang PM, Izumo S. Apoptosis and heart failure: a critical review of the literature. Circ Res. 2000;86(11):1107-13. (Pubitemid 30396034)
114. Terrovitis J, Lautamaki R, Bonios M, et al. Noninvasive quantification and optimization of acute cell retention by in vivo positron emission tomography after intramyocardial cardiac-derived stem cell delivery. J Am Coll Cardiol. 2009;54 (17):1619-26.
115. Chan AT, Abraham MR. SPECT and PET to optimize cardiac stem cell therapy. J Nucl Cardiol. 2012;19(1):118-25.
116. Gildehaus FJ, Haasters F, Drosse I, et al. Impact of indium-111 oxine labelling on viability of human mesenchymal stem cells in vitro, and 3D cell-Tracking using SPECT/CT in vivo. Mol Imaging Biol. 2011;13(6):1204-14.
117. Higuchi T, Anton M, Dumler K, et al. Combined reporter gene PET and iron oxide MRI for monitoring survival and localization of transplanted cells in the rat heart. J Nucl Med. 2009;50 (7):1088-94.
118. Bengel FM. Noninvasive imaging of cardiac gene expression and its future implications for molecular therapy. Mol Imaging Biol. 2005;7(1):22-9. (Pubitemid 41348872)
119. Zhang SJ,Wu JC. Comparison of imaging techniques for tracking cardiac stem cell therapy. J Nucl Med. 2007;48(12):1916-9. (Pubitemid 350232321)
120. Hofmann M, Wollert KC, Meyer GP, et al. Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation. 2005;111(17):2198-202. (Pubitemid 40632435)